SK Investment Vina III, a subsidiary of South Korea’s third-largest conglomerate SK Group, is looking to acquire a 65 per cent stake in Imexpharm Pharmaceutical.
Ukraine’s leading investment bank Dragon Capital has cut its GDP forecast for Ukraine in 2024 in half to 4% y/y in anticipation of another year of war, The New Voice of Ukraine reported on December.